Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00776009
Other study ID # CRIT124EUS21
Secondary ID
Status Completed
Phase Phase 4
First received October 16, 2008
Last updated June 6, 2011
Start date October 2008
Est. completion date December 2008

Study information

Verified date June 2011
Source Novartis
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This study will evaluate the efficacy and safety of Dex-Methylphenidate Extended Release 30 mg compared to 20 mg in pediatric patients ages 6-12 with Attention-Deficit Hyperactivity Disorder (ADHD) in a 12-hour laboratory classroom setting.


Recruitment information / eligibility

Status Completed
Enrollment 165
Est. completion date December 2008
Est. primary completion date December 2008
Accepts healthy volunteers No
Gender Both
Age group 6 Years to 12 Years
Eligibility Inclusion Criteria:

- Male and female subjects aged 6-12 years, inclusive.

- Subjects meeting the DSM-IV criteria for primary diagnosis of ADHD-Combined type, or predominantly hyperactive-impulsive subtype, as established by the K-SADS-PL (Kiddie Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version). If a DSM-IV-defined ADHD diagnosis is difficult to establish due to possible co-morbidity, the subject will not be enrolled into the study.

- Subjects should be on a stabilized total daily dose or nearest equivalent of 40-60 mg methylphenidate or 20-30 mg of d-methylphenidate for at least two weeks prior to Screening visit.

Exclusion Criteria:

- Subject or subject's guardian unable to understand or follow instructions necessary to participate in the study.

- Diagnosed with or history of a tic disorder or Tourette's syndrome.

- History of seizure disorder.

- The presence of a known medical condition that would preclude the use of methylphenidate.

- A history (within the past year) or presence of clinically significant cardiovascular, cerebrovascular, renal, hepatic, gastrointestinal, pulmonary, immunological, hematological, endocrine, or neurological disease.

- ALT (Alanine Amino Transferase), AST (Aspartate Amino Transferase), GGT (Gamma glutamyl transferase) or serum creatinine greater then 2X the ULN (Upper Limit of Normal) at Screening.

- A history of psychiatric illness or substance use disorder (e.g., schizophrenia, bipolar disorder, autism, abuse or dependence, depression, severe Conduct Disorder or severe Oppositional defiant disorder)

- Subjects who have participated in an investigational trial within the past 4 weeks (28 days)

- Subjects who are currently taking antidepressants or other psychotropic medication.

- Subjects who have initiated psychotherapy during the three months prior to randomization.

- Subjects with a positive urine drug screen.

- Subjects who have a history of poor response or intolerance to methylphenidate or d-methylphenidate.

Other protocol-defined inclusion/exclusion criteria may apply

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Attention Deficit Disorder with Hyperactivity
  • Attention-Deficit/Hyperactivity Disorder (ADHD)
  • Hyperkinesis

Intervention

Drug:
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)
10 mg and/or 20 mg capsules
Placebo
Placebo Comparator

Locations

Country Name City State
United States Florida Clinical Research Center, LLC Bradenton Florida
United States Bayou City Research Houston Texas
United States Claghorn-Lesem Research Clinic Houston Texas
United States Center for Psychiatry and Behavioral Medicine, Inc. Las Vegas Nevada
United States Clinical Study Center, LLC Little Rock Arkansas
United States Behavioral Neurology Lubbock Texas
United States Vince and Associates Clinical Research Overland Park Kansas
United States Miami Research Associates South Miami Florida

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Pre-dose in the Swanson, Kotkin, Agler, M Flynn, and Pelham (SKAMP) Combined Attention and Deportment Scores at 10, 11, and 12 Hour (Averaged) Post-dose SKAMP is a 13-item rating scale that measures classroom manifestations of ADHD consisting of 2 subscales (7 items for Attention and 6 items for Deportment) used to generate a score at Hours 10, 11 and 12 on Day 7 of Weeks 1, 2 and 3. The ratings were based on both frequency and quality of specific behaviors. The rating scale is 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 78. The reported measure is the difference from baseline of the 2 combined subscores averaged over Hours 10, 11 and 12. A negative score indicates improvement. Pre-dose to 10, 11, and 12 hours post-dose No
Secondary Change From Pre-dose in the Swanson, Kotkin, Agler, M Flynn, and Pelham (SKAMP) Attention Score at 10, 11, and 12 Hour (Averaged) Post-dose SKAMP is a 13-item rating scale consisting of 2 subscales (7-items for Attention and 6-items for Deportment) that measures classroom manifestations of ADHD. SKAMP was used to generate a score on the Attention subscale at Hours 10, 11, and 12 on Day 7 of Weeks 1, 2, and 3. The rating scale is 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 42 for the Attention subscale. The reported measure is the difference from baseline of the subscore averaged over Hours 10, 11, and 12. A negative score indicates improvement. Pre-dose to 10, 11, and 12 hours post-dose No
Secondary Change From Pre-dose in the Swanson, Kotkin, Agler, M Flynn, and Pelham (SKAMP) Deportment Score at 10, 11, and 12 Hour (Averaged) Post-dose SKAMP is a 13-item rating scale consisting of 2 subscales (7-items for Attention and 6-items for Deportment) that measures classroom manifestations of ADHD. SKAMP was used to generate a score on the Deportment subscale at Hours 10, 11, and 12 on Day 7 of Weeks 1, 2, and 3. The rating scale is 0 (normal, no impairment) to 6 (maximum impairment) for a total possible combined score of 0 to 36 for the Deportment subscale. The reported measure is the difference from baseline of the subscore averaged over Hours 10, 11, and 12. A negative score indicates improvement. Pre-dose to 10, 11, and 12 hours post-dose No
Secondary Change From Pre-dose in the Permanent Product Measure of Performance of Measurement (PERMP) Math Test-Attempted Score at 10, 11, and 12 Hours (Averaged) Post-dose Permanent Product Measure of Performance of Measurement (PERMP) is an age-adjusted, paper-and-pencil math test consisting of 5 pages of 80 math problems each presented in ascending order of difficulty (requiring addition, subtraction, multiplication, and division computations, respectively) during a 10-minute time period. At the end of the 10-minute math test, papers are collected and scored; the number of problems attempted and the number of problems correctly answered are generated as objective measures related to "academic productivity." A positive score indicates improvement. Pre-dose to 10, 11, and 12 hours post-dose No
Secondary Change From Pre-dose in the Permanent Product Measure of Performance of Measurement (PERMP) Math Test-Correctly Answered Score at 10, 11, and 12 Hours (Averaged) Post-dose Permanent Product Measure of Performance of Measurement (PERMP) is an age-adjusted, paper-and-pencil math test consisting of 5 pages of 80 math problems each presented in ascending order of difficulty (requiring addition, subtraction, multiplication, and division computations, respectively) during a 10-minute time period. At the end of the 10-minute math test, papers are collected and scored; the number of problems attempted and the number of problems correctly answered are generated as objective measures related to "academic productivity." A positive score indicates improvement. Pre-dose to 10, 11, and 12 hours post-dose No
See also
  Status Clinical Trial Phase
Completed NCT02150668 - Efficacy of an Organizational Skills Intervention for Middle School Students With ADHD N/A
Completed NCT00631280 - Does Active Parent Involvement in Deliberation and Choice Improve Medication Persistence for Their Child With ADHD N/A
Recruiting NCT05809388 - Virtual Reality for Parent Training Intervention N/A
Recruiting NCT00252278 - Effect of Atomoxetine on ADHD-Related Insomnia in Children and Adolescents Phase 4
Completed NCT04016779 - Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD Phase 3
Completed NCT00307268 - Evaluating Clinical Outcomes of Treatment Effectiveness for Children and Adults With ADHD N/A
Completed NCT01107496 - Evaluation of Immediate-Release Viloxazine in Adults With ADHD Phase 1/Phase 2
Completed NCT04786990 - Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD Phase 4
Completed NCT00711724 - Comparison of Self and Clinician Administered Rating Scales in Patients With ADHD N/A
Completed NCT00475735 - A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED) Phase 2
Recruiting NCT06215144 - Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD Phase 2/Phase 3
Completed NCT02633527 - Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD Phase 2
Withdrawn NCT00323700 - A Naturalistic Prospective Study of Treatment Effectiveness for Attention-Deficit/Hyperactivity Disorder (ADHD) N/A
Not yet recruiting NCT04532190 - Finding Alternatives to Standard Treatment for Attention-Deficit Hyperactivity Disorder N/A
Withdrawn NCT00931398 - Treatment of College Students With Attention-Deficit/Hyperactivity Disorder (ADHD) Using OROS Methylphenidate Phase 4